Galapagos Affirms Q4 Guidance, Lowers Full-Year Cash Burn Projections

Jan 18, 2006

NEW YORK, Jan. 18 (GenomeWeb News) - Galapagos today said that it expects its fourth-quarter 2005 revenues to meet previous guidance of €7.7 million ($9.3 million), and that it expects its full-year cash burn to be lower than its guidance of €7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Main menu